German China

Clinical Research Thermo Fisher Scientific Inaugurates New Bioanalytical Lab in USA

Source: Press release Thermo Fisher Scientific

Thermo Fisher Scientific’s new bioanalytical lab is located in Richmond, Virginia and will help to accelerate the firm’s drug discovery process and expand its clinical research operations in the region.

Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia, USA.
Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia, USA.
(Source: ©copyright John Still for Thermo Fisher Scientific)

North Carolina/USA – Thermo Fisher Scientific has expanded its clinical research operations with the opening of a state-of-the art bioanalytical lab in Richmond, Virginia. The new unit will support increasing demand across biopharma for consistent, high-quality laboratory services to accelerate drug development. The 59,000-square-foot facility is part of the previously announced 97-million-dollar investment by the company to expand its bioanalytical laboratory operations in Richmond and add more than 500 jobs over the next three years.

The current laboratory services operation in Richmond, which Thermo Fisher acquired through the purchase of PPD in December 2021, now comprises more than 350,000 square feet, making it one of the largest laboratories of its kind in the world. The entire Richmond operation employs about 1,300 local professionals, including Ph.D.-level scientists, analytical laboratory staff and other scientific professionals. The bulk of the expansion with this new facility will occur in liquid chromatography-mass spectrometry for drug discovery through to clinical testing, as well as subsequent enhancements in cell and gene therapy, biomarkers, vaccine sciences and immunochemistry.

“The ongoing expansion of our bioanalytical operations builds on the growth of our drug development expertise over nearly four decades, enabling us to provide customers with high-quality lab services to advance their clinical research programs,” said David M. Johnston, Ph.D., senior vice president and president, clinical research, Thermo Fisher Scientific. “These additions will enable us to meet the growing needs of our customers delivering life-changing therapies.”

(ID:48676051)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent